Publications by authors named "Melinda L Telli"

54Publications

BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

Authors:
Melinda L Telli

Lancet Oncol 2020 Aug 27. Epub 2020 Aug 27.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30431-9DOI Listing
August 2020

Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.

JCO Oncol Pract 2020 01 15;16(1):e37-e55. Epub 2019 Oct 15.

Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00221DOI Listing
January 2020

Induced Pluripotent Stem Cell-Based Cancer Vaccines.

Front Immunol 2019 8;10:1510. Epub 2019 Jul 8.

Cardiovascular Institute, School of Medicine, Stanford University, Stanford, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.01510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628907PMC
July 2019

NCCN Guidelines Updates: Breast Cancer.

J Natl Compr Canc Netw 2019 05;17(5.5):552-555

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.5006DOI Listing
May 2019

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

J Clin Oncol 2018 11 21;36(31):3134-3143. Epub 2018 Sep 21.

Cristina Cruz and Judith Balmaña, Vall d'Hebron Hospital; Cristina Cruz, Alba Llop-Guevara, Joaquín Arribas, Ana Vivancos, Violeta Serra, and Judith Balmaña, Vall d'Hebron Institute of Oncology; José A. Pérez Fidalgo, Ana Lluch, Joaquín Arribas, and Violeta Serra, Centro de Investigación Biomédica en Red; Joaquín Arribas, Institució Catalana de Recerca i Estudis Avançats, Barcelona; José A. Pérez Fidalgo and Ana Lluch, Hospital Clínico de Valencia, Valencia; Cristian Fernández, Carmen Kahatt, Carlos M. Galmarini, Arturo Soto-Matos, Vicente Alfaro, and Aitor Pérez de la Haza, PharmaMar, Madrid; Silvia Antolin, Complejo Universitario Hospitalario La Coruña, La Coruña; Rafael Lopez, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Judy E. Garber, Dana Farber Cancer Institute; Nadine M. Tung, Beth Israel Deaconess Medical Center; José Baselga and Steven J. Isakoff, Massachusetts General Hospital Cancer Center, Boston, MA; Banu K. Arun, MD Anderson Cancer Center, Houston, TX; Melinda L. Telli, Stanford University School of Medicine, Stanford, CA; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; and Linda Vahdat, Weill Cornell Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209089PMC
November 2018

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

J Clin Oncol 2018 Sep 20:JCO2017748392. Epub 2018 Sep 20.

Aditya Bardia, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; Scott Cameron and Serena Liao, Novartis Institutes for BioMedical Research, Cambridge, MA; Marina Parton, The Royal Marsden Hospital, London, United Kingdom; Sherko Kümmel, Kliniken Essen-Mitte, Essen, Germany; Laura G. Estévez, Centro Integral Oncológico Clara Campal; Javier Cortés, University Hospital Ramón y Cajal, Madrid; Javier Cortés,Vall d'Hebron Institute of Oncology, Barcelona; Manuel Ruiz-Borrego, Hospital Universitario Virgen del Rocío, Seville; Paloma Martin-Martorell, Hospital Clínico Universitario de Valencia, Valencia; Rafael López, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Chiun-Sheng Huang, National Taiwan University Hospital, National Taiwan University College of Medicine; Shin-Cheh Chen, Chang Gung Memorial Hospital, Taipei, Republic of China; Melinda L. Telli, Stanford University School of Medicine, Stanford; Sara A. Hurvitz, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Roohi Ismail-Khan, Moffitt Cancer Center, Tampa, FL; Ingrid A. Mayer, Vanderbilt-Ingram Cancer Center, Nashville, TN; Daniel Carreon, Novartis Pharmaceuticals Corporation, East Hanover, NJ; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; and Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.8392
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.8392DOI Listing
September 2018

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

J Clin Oncol 2018 08 22;36(23):2433-2443. Epub 2018 May 22.

Neelima Denduluri, The US Oncology Network, Virginia Cancer Specialists; Jamie N. Holloway, Georgetown Breast Cancer Advocates, Arlington; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Mariana Chavez-MacGregor and Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston, TX; Melinda L. Telli, Stanford University School of Medicine, Stanford; Arti Hurria, City of Hope, Duarte, CA; Andrea Eisen and Maureen E. Trudeau, Sunnybrook Odette Cancer Centre; Andrea Eisen and Maureen E. Trudeau, Cancer Care Ontario, Toronto, Ontario, Canada; Stephanie L. Graff, Sarah Cannon Cancer Institute HCA Midwest Health, Kansas City, MO; Michael J. Hassett, Tari A. King, and Ann H. Partridge, Dana-Farber Cancer Institute; Tari A. King, Brigham & Women's Cancer Center, Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.8604
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.8604DOI Listing
August 2018

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.

Proc Natl Acad Sci U S A 2017 12 11;114(52):13792-13797. Epub 2017 Dec 11.

Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH 44106;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1713728114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748193PMC
December 2017

Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer.

J Oncol Pract 2017 05;13(5):305-307

Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.023341DOI Listing
May 2017

Genetics of triple-negative breast cancer: Implications for patient care.

Curr Probl Cancer 2016 Mar - Aug;40(2-4):130-140. Epub 2016 Sep 23.

Stanford University School of Medicine, Department of Medicine, Stanford, CA; Stanford University School of Medicine, Department of Health Research and Policy, Stanford, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2016.09.007DOI Listing
December 2017

Reply to L. Del Mastro and A. Prat.

J Clin Oncol 2017 04 17;35(10):1139. Epub 2017 Jan 17.

Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.9758
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.9758DOI Listing
April 2017

Breast Cancer After Hodgkin Lymphoma: The Price of Success.

Oncology (Williston Park) 2016 12;30(12):1072-3

View Article

Download full-text PDF

Source
December 2016

Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.

Ann Surg Oncol 2016 10 11;23(10):3310-6. Epub 2016 Jul 11.

Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-016-5319-8DOI Listing
October 2016

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

J Clin Oncol 2016 07 18;34(20):2416-27. Epub 2016 Apr 18.

Neelima Denduluri, US Oncology Network, Virginia Cancer Specialists, Arlington; Jamie N. Holloway, Patient Representative, Arlington; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen and Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Ontario, Canada; Arti Hurria, City of Hope, Duarte; Melinda L. Telli, Stanford University, Palo Alto, CA; Tari A. King, Dana-Farber/Brigham and Women's Cancer Center; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.0182DOI Listing
July 2016

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

J Clin Oncol 2015 Jun 6;33(17):1895-901. Epub 2015 Apr 6.

Melinda L. Telli, Kristin C. Jensen, Shaveta Vinayak, Allison W. Kurian, Jafi A. Lipson, Patrick J. Flaherty, Elizabeth A. Schackmann, Irene L. Wapnir, Robert W. Carlson, Pei-Jen Chang, and James M. Ford, Stanford University School of Medicine, Stanford; Bobbie Head, Marin Specialty Care, Greenbrae, CA; Kirsten Timms, Victor Abkevich, Julia E. Reid, and Anne-Renee Hartman, Myriad Genetics, Salt Lake City, UT; Joseph A. Sparano, Albert Einstein College of Medicine, New York, NY; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia, PA; Barbara Haley, University of Texas Southwestern Medical Center, Dallas, TX; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; and Judith Manola, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451172PMC
June 2015

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.

Cancer Discov 2015 May 13;5(5):488-505. Epub 2015 Mar 13.

Breakthrough Breast Cancer Research Unit, King's College London, London, United Kingdom. Department of Research Oncology, King's Health Partners AHSC, Life Sciences and Medicine, King's College London, London, United Kingdom. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490184PMC
May 2015

The future of breast cancer systemic therapy: the next 10 years.

J Mol Med (Berl) 2015 Feb 9;93(2):119-25. Epub 2015 Jan 9.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305-5826, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00109-014-1238-yDOI Listing
February 2015

(18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.

Radiology 2014 Nov 16;273(2):549-59. Epub 2014 Jul 16.

From the Division of Nuclear Medicine and Molecular Imaging (A.I., C.M., E.M.), Molecular Imaging Program at Stanford (B.S., F.T.C.), Division of Medical Oncology (M.L.T.), and Departments of Radiology, Bioengineering, and Materials Science and Engineering (S.S.G.), Stanford University Medical Center, 300 Pasteur Dr, Room H-0101, Stanford, CA 94305.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.14140028DOI Listing
November 2014

Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.

AMIA Jt Summits Transl Sci Proc 2013 18;2013:62. Epub 2013 Mar 18.

Department of Radiology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083372PMC
December 2013

Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer.

Authors:
Melinda L Telli

J Clin Oncol 2013 Oct 3;31(29):3613-5. Epub 2013 Sep 3.

Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.51.0313
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.51.0313DOI Listing
October 2013

Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.

J Am Med Inform Assoc 2013 Nov-Dec;20(6):1059-66. Epub 2013 Jun 19.

Department of Radiology, Stanford University Medical Center, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/amiajnl-2012-001460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822111PMC
December 2013

PARP inhibitors in cancer: moving beyond BRCA.

Authors:
Melinda L Telli

Lancet Oncol 2011 Sep 19;12(9):827-8. Epub 2011 Aug 19.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S147020451170236
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(11)70236-4DOI Listing
September 2011

Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?

Heart Fail Clin 2011 Jul 14;7(3):333-44. Epub 2011 May 14.

Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Falk CVRC, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155171361100025
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2011.03.005DOI Listing
July 2011

Trastuzumab-related cardiac dysfunction.

J Natl Compr Canc Netw 2011 Feb;9(2):243-9

Department of Medicine, Division of Medical Oncology , Stanford University, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2011.0019DOI Listing
February 2011

PARP inhibitors in breast cancer.

Clin Adv Hematol Oncol 2010 Sep;8(9):629-35

Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
September 2010

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry.

Breast Cancer Res Treat 2011 Jun 19;127(2):471-8. Epub 2010 Oct 19.

Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-010-1173-8
Publisher Site
http://dx.doi.org/10.1007/s10549-010-1173-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349378PMC
June 2011

Novel treatment approaches for triple-negative breast cancer.

Clin Breast Cancer 2010 ;10 Suppl 1:E16-22

Department of Medicine, Stanford University School of Medicine, CA 94305-5820, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209117009
Publisher Site
http://dx.doi.org/10.3816/CBC.2010.s.003DOI Listing
October 2010

Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls.

Cancer Epidemiol Biomarkers Prev 2010 Feb;19(2):605-13

Department of Pediatrics, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-09-0896DOI Listing
February 2010

First-line chemotherapy for metastatic breast cancer.

Clin Breast Cancer 2009 Jun;9 Suppl 2:S66-72

Department of Medicine, Division of Medical Oncology, Stanford University, CA, USA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/27/23/3764.full.pdf
Web Search
http://jco.ascopubs.org/content/12/2/336.full.pdf
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S152682091170688
Publisher Site
http://dx.doi.org/10.3816/CBC.2009.s.007DOI Listing
June 2009

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

J Clin Oncol 2007 Aug;25(23):3525-33

Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.11.0106DOI Listing
August 2007

Phyllodes tumors of the breast: natural history, diagnosis, and treatment.

J Natl Compr Canc Netw 2007 Mar;5(3):324-30

Department of Medicine, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/5/3/324.full.pdf
Web Search
http://dx.doi.org/10.6004/jnccn.2007.0027DOI Listing
March 2007